Enrich Layer logo svg
ADARx Pharmaceuticals Inc. logo

ADARx Pharmaceuticals Inc.

Our vision is to provide effective and safe RNA therapeutics to patients who suffer from intractable diseases.

Last updated: . For recent data, use our API.

Overview

ADARx Pharmaceuticals, Inc., located in San Diego, is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx has developed proprietary RNA targeting platforms and oligonucleotide delivery technologies for inhibition, degradation, and editing disease-causing mRNA. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated diseases and central nervous system diseases. We are well-financed by a syndicate of renowned VC firms.

ADARx currently has multiple active programs in development. Our lead candidate is at the clinical stage.

Funding rounds

Disclosed funding: $413.5M across 7 rounds. Latest: Venture Round, 1 Feb 2025.

DateTypeAmount
1 Feb 2025Venture Round$50M
More funding rounds via API
Get company data via API

Get company records through the Enrich Layer API. These pages show previews only.

Office locations

ADARx Pharmaceuticals Inc. FAQ

As of 2026-10-23, ADARx Pharmaceuticals Inc. has 71 employees, based on the Enrich Layer count of person profiles that list ADARx Pharmaceuticals Inc. as their current employer. Its listed company size band is 51 to 200.
As of 2026-10-23, ADARx Pharmaceuticals Inc. is headquartered in San Diego, CA, US.
ADARx Pharmaceuticals Inc. was founded in 2019.
As of 2026-10-23, ADARx Pharmaceuticals Inc. is classified in the Biotechnology Research industry.
ADARx Pharmaceuticals, Inc., located in San Diego, is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx has developed proprietary RNA targeting platforms and oligonucleotide delivery technologies for inhibition, degradation, and editing disease-causing mRNA. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated diseases and central nervous system diseases. We are well-financed by a syndicate of renowned VC firms.
As of 2026-10-23, ADARx Pharmaceuticals Inc.'s official website is http://adarx.com/.
As of 2026-10-23, ADARx Pharmaceuticals Inc. is a privately held company.